Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Don’t Buy Las Vegas Sands Right Now- Or Its Peers

Wynn and Melco Crown are at least profitable, but as with Las Vegas Sands they look pricy with trailing earnings multiples of more than 25. Wynn’s earnings actually fell 42% last quarter compared to the fourth quarter of 2011, partly due to a small decrease in revenue but mostly due to narrower net margins. Again, even if the company hits Street targets for 2014 it would be trading at 18 times earnings at the current stock price, and so would need more improvements going forward and so we think that it’s a bit too speculative. Melco Crown is up 65% in the last year and currently carries trailing and forward P/Es of 31 and 19, respectively. It actually reported an increase in revenue in its most recent quarter compared to the same period in the previous year, but as with Las Vegas Sands net income was less responsive. In addition, Melco Crown’s focus on Macau leaves it less geographically diversified and more dependent on the macroeconomy, as shown by its beta of 2.6.

Casinos in generally don’t look like attractive investments right now. MGM and Caesars are, in the eyes of the sell-side, at least two years from breaking even and we’d be quite concerned about their leverage as well. The other three companies, including Las Vegas Sands, are valued at quite high levels relative to their historical earnings and yet have not been delivering much earnings growth- and that is with Las Vegas Sands having opened a new location, which should theoretically have boosted net income as well as net revenues. As a result we can’t recommend Las Vegas Sands or any of its peers from a value perspective.

Disclosure: I own no shares of any stocks mentioned in this article.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!